Category Archives: "News"

  1. Home
  2. INforMS
  3. Page 9
Dec 05, 2019
FDA approves first generics for common multiple sclerosis drug
INforMS
The FDA has approved 3 applications for generics of fingolimod (Gilenya, Novartis). These are the first generics of the drug, which treats [...]
Elizabeth Porco
Read More
...63
0
Dec 01, 2019
Results for Genentech’s Satralizumab in Neuromyelitis Optica Spectrum
INforMS, Partners
Satralizumab demonstrated robust efficacy, sustained for 144 weeks, in significantly reducing the risk of relapse in combination with [...]
Elizabeth Porco
Read More
...49
0
Nov 26, 2019
NeurologyLive™ adds CMSC to its Strategic Alliance Partnership program
INforMS, Partners
CRANBURY, N.J.--(BUSINESS WIRE)--NeurologyLive™, a multimedia platform dedicated to providing health care professionals treating [...]
Elizabeth Porco
Read More
...52
0
Nov 11, 2019
In Memoriam: Alan Mandel
CMSC PR
Our dear friend and colleague Alan Mandel passed away early Monday morning, November 4, 2019. He fought hard in his battle against PML and [...]
Elizabeth Porco
Read More
...51
0
Oct 07, 2019
Kessler scientists receive grant to study exercise benefits in multiple sclerosis
INforMS
East Hanover, NJ. October 7, 2019. With a grant from the Consortium of Multiple Sclerosis Centers, John DeLuca, PhD, Helen Genova, PhD, of [...]
Elizabeth Porco
Read More
...50
0
Sep 17, 2019
EMD Serono initiates pivotal Phase III program for investigational Evobrutinib in RMS
INforMS, Partners
ROCKLAND, Mass., Sept. 10, 2019 /PRNewswire/ -- EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. [...]
Elizabeth Porco
Read More
...49
0
Sep 12, 2019
Genentech presents new six-year Ocrevus (Ocrelizumab) data
INforMS, Partners
Post-hoc analysis from a Phase III open-label extension study showed a 42% reduction in the risk of PPMS patients needing a wheelchair [...]
Elizabeth Porco
Read More
...48
0
Sep 11, 2019
Genentech’s Satralizumab significantly reduced relapse risk
INforMS, Partners
Pivotal Phase III SAkuraStar study shows 55% reduction in the risk of relapse for satralizumab monotherapy versus placebo presented at [...]
Elizabeth Porco
Read More
...48
0
Sep 10, 2019
Janet Brown obituary
CMSC PR
Janet Brown ( December 30, 1964 - September 08, 2019 ) Ms. Janet Marie Brown, MSN, FNP-BC, MSCN, age 54, of Murfreesboro, TN [...]
Elizabeth Porco
Read More
...51
0
Sep 09, 2019
Genentech presents new Ocrevus (Ocrelizumab) biomarker data
INforMS, Partners
Blood neurofilament light chain (NfL) levels were significantly lowered following Ocrevus treatment in analyses of Phase III studies in RMS [...]
Elizabeth Porco
Read More
...50
0
  • (201) 487-1050
  • 3 University Plz Dr Ste 116, Hackensack, NJ 07601
  • info@mscare.org

CMSC provides leadership in clinical research and education; develops vehicles to share information and knowledge among members; disseminates information to the health care community and to persons affected by MS.

Contact Us
Contact Us





I have a question about

First

Last




Feel Free To contact Us
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam molestie, tellus id pellen tesque feugiat, sem sem cursus orci, a placerat ante ante nec massa. consectetuer adipiscing elit.

+1-222-333-4444

New York, NY 10123 USA

Mon - Sat 9:00 AM